According to a new report, published by KBV research, The Global Extracorporeal CO2 Removal Devices Market size is expected to reach $132.8 million by 2030, rising at a market growth of 7.3% CAGR during the forecast period.
The Bridge to Lung Transplant segment acquired the highest revenue in the Global Extracorporeal CO2 Removal Devices Market, By Application in 2022 thereby, achieving a market value of $54.7 million by 2030. One of the main drivers of this growth is the increasing prevalence of advanced lung diseases and the limited availability of donor organs. Patients with chronic lung diseases, such as idiopathic pulmonary fibrosis (IPF) or chronic obstructive pulmonary disease (COPD), often face long waiting times for lung transplantation. ECCO2R therapy helps these patients by providing essential respiratory support, reducing the risk of further lung damage, and improving overall health while on the transplant waiting list.
The Clinics segment is registering a CAGR of 7.9% during (2023 - 2030). Clinics now utilize ECCO2R for patients with chronic respiratory conditions, such as severe exacerbations of chronic obstructive pulmonary disease (COPD), allowing for proactive disease management and reducing hospital admissions. ECCO2R can be a valuable tool for providing temporary respiratory support to patients with fluctuating lung function, especially those with chronic respiratory diseases.
The Extracorporeal CO2 Machines segment acquired maximum revenue in the Global Extracorporeal CO2 Removal Devices Market, By Product in 2022 thereby, achieving a market value of $68.5 million by 2030. Simplified ECCO2R technology has led to increased reliability and fewer technical failures. Complex devices may be prone to technical issues, disrupting patient care and leading to suboptimal outcomes. Technical simplification has minimized the risk of malfunctions, ensuring that ECCO2R therapy remains stable and effective. Simplified extracorporeal CO2 machines are also easier to maintain and service, reducing downtime and the need for highly specialized technical support.
The Arteriovenous segment would exhibit a CAGR of 7.9% during (2023 - 2030). The arteriovenous segment recorded the maximum revenue share in the extracorporeal CO2 removal devices market. The growth in the segment is a result of the increasing use of arteriovenous (AV) ECCO2R and its ability to provide highly efficient CO2 removal. By accessing blood directly from an artery, AV ECCO2R can extract CO2 more rapidly and effectively.
The North America region dominated the Global Extracorporeal CO2 Removal Devices Market, By Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $48.9 million by 2030. The Europe market is anticipated to grow at a CAGR of 7.1% during (2023 - 2030). Additionally, The Asia Pacific market would exhibit a CAGR of 8.3% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/extracorporeal-co2-removal-devices-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country-wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Medtronic PLC, Getinge AB, Fresenius Medical Care AG & Co. KGaA , Medica S.P.A., Aferetica srl, LivaNova PLC, ESTOR S.P.A., X-COR Therapeutics
By Application
By End-Use
By Product
By Access
By Geography
Companies Profiled
Unique Offerings 
